(Q54198584)

26 May 2018

title

Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer. (English)

1 reference

26 May 2018

1 reference

Yukiko Tabuchi

1

1 reference

26 May 2018

Masafumi Shimoda

2

1 reference

26 May 2018

Naofumi Kagara

3

1 reference

26 May 2018

Yasuto Naoi

4

1 reference

26 May 2018

Tomonori Tanei

5

1 reference

26 May 2018

Atsushi Shimomura

6

1 reference

26 May 2018

Kenzo Shimazu

7

1 reference

26 May 2018

Seung Jin Kim

8

1 reference

26 May 2018

Shinzaburo Noguchi

9

1 reference

26 May 2018

language of work or name

English

0 references

publication date

25 April 2016

1 reference

26 May 2018

Breast Cancer Research and Treatment

published in

1 reference

26 May 2018

volume

157

1 reference

26 May 2018

issue

1

1 reference

26 May 2018

page(s)

55-63

1 reference

26 May 2018

Unique human tumor antigens: immunobiology and use in clinical trials

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

The epithelial mucin, MUC1, of milk, mammary gland and other tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

MUC1 and the immunobiology of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Natural innate and adaptive immunity to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Human tumor cell lysates as a protein source for the detection of cancer antigen-specific humoral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-016-3801-4

10.1007/S10549-016-3801-4

21 January 2018

Identifiers

DOI

1 reference

26 May 2018

1 reference

26 May 2018